News
EQS-News: Evotec announces agreement with Janssen to develop immune-based therapies
New waters_connect System Monitoring Software Maximizes Productivity with Real-Time, Cloud-Native Lab Management
Waters Corporation (NYSE:WAT) today announced waters_connect™ System Monitoring, a new Software-as-a-Service (SaaS) application that enables laboratory managers and analysts to monitor the
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Dexcom G6 Real-Time CGM System Now Available to All Clients With Type 1 Diabetes Covered Under the Non-Insured Health Benefits Program
Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (rtCGM), is pleased to announce that coverage for Dexcom G6 rtCGM System on the Non-Insured Health Benefits
Dexcom G6 Real-Time CGM System Now Available to All Clients With Type 1 Diabetes Covered Under the Non-Insured Health Benefits Program
Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (rtCGM), is pleased to announce that coverage for Dexcom G6 rtCGM System on the Non-Insured Health Benefits
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Actress and Beauty Entrepreneur Peyton List Sets Her Sights on 2023 with Upgraded Vision from Life-Changing EVO ICL Lenses
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses, today announced a partnership with actress and beauty entrepreneur, Peyton List, to
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Novocure: LUNAR-Studie erreicht primären Endpunkt für Gesamtüberleben bei nicht kleinzelligem Lungenkrebs
Wie Novocure (NASDAQ: NVCR) heute mitteilte, hat die LUNAR-Studie ihren primären Endpunkt erreicht und eine statistisch signifikante und klinisch bedeutsame Verbesserung des Gesamtüberlebens im
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Agilent Investing $725 Million to Expand State-of-the-Art Manufacturing Capacity for Production of Nucleic Acid-Based Therapeutics
Agilent Technologies Inc. (NYSE: A) today announced it is investing approximately $725 million to double manufacturing capacity of therapeutic nucleic acids in response to rapid growth of the $1
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
EQS-News: MorphoSys AG: MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024
EQS-News: MorphoSys AG: MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
EQS-News: MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability
EQS-News: MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability